Neuroleptics for Refractory Pain

What They Are

Neuroleptics (also called antipsychotics) are a class originally developed for management of psychosis. Use in pain is largely off-label and restricted to specific scenarios — they are not part of chronic pain guidelines as first or second line. First-generation (typical) agents — chlorpromazine and haloperidol — have established use in psychiatry and, in pain, occasional application in migraine status in the emergency setting. Second-generation (atypical) agents — olanzapine, quetiapine, risperidone — have use almost entirely restricted to palliative care (refractory nausea, end-of-life suffering). The exception with robust evidence is olanzapine for chemotherapy-induced nausea — a specific indication, not analgesia per se.

Mechanism of Action

The central mechanism is D2 dopamine receptor antagonism in the mesolimbic and nigrostriatal pathways — the basis of the antipsychotic effect and of central antiemesis. In pain, the hypothesis of analgesic action invokes central dopaminergic modulation of nociceptive pathways, but the evidence for a specific analgesic mechanism is weak compared with opioids, anticonvulsants, and antidepressants. Clinical heterogeneity arises from multireceptor antagonism: in addition to D2, there is blockade of 5-HT2 (sedation, metabolic effects), alpha-1 adrenergic (hypotension — chlorpromazine), H1 (sedation, weight gain), and muscarinic (anticholinergic — dry mouth, urinary retention, cognitive risk in older adults). In migraine emergencies, the effect combines D2 antagonism, sedation, and possible trigeminal modulation; in chemotherapy-induced nausea, D2 + 5-HT2 at the vomiting center sustains antiemetic efficacy — a distinct indication from "treating pain."

Scientific Evidence

The honest reading is uncomfortable for those who expect to see neuroleptics legitimized as analgesics: in chronic nociceptive or neuropathic pain, the evidence is low or absent; in specific emergency and palliative scenarios, there is reasonable support. The relevant question is always "which molecule, in which indication, in which context."

In refractory migraine in the emergency setting, Lobo et al. (Cephalalgia 2015) and Friedman et al. (Headache 2014) support moderate evidence for chlorpromazine and haloperidol IV in migraine status after failure of triptans, parenteral NSAIDs, and antiemetics. The use is occasional, hospital-based, and not chronic — not prophylaxis or outpatient treatment. In chemotherapy-induced nausea, Navari et al. (N Engl J Med) consolidated olanzapine as a high-efficacy add-on to the standard antiemetic regimen in highly emetogenic regimens — evidence of high quality, but the indication is antiemesis, not analgesia. In palliative care, Hardy et al. (Palliat Med) describes use in refractory pain with existential suffering — a specialized indication outside the scope of outpatient chronic pain.

The counterpoint: NICE and IASP do not include neuroleptics in protocols for chronic primary pain, low back pain, fibromyalgia, or neuropathic pain. The absence reflects lack of evidence and unfavorable risk profile for chronic use; critical reviews flag low-dose quetiapine for insomnia in chronic pain as a popular practice disconnected from the scientific basis.

Restricted Indications

The indications below are the totality of the scenarios in which, with the current literature, it makes sense to consider neuroleptics in pain. The point is not to broaden use — it is to have clarity about the boundaries where the class has any basis.

How They Are Used

Use in pain is almost always in a hospital or specialized palliative care setting. Self-prescription or chronic outpatient use in non-palliative pain is an inadequate practice. Mandatory monitoring — ECG, extrapyramidal symptoms, metabolic parameters — is incompatible with routine use without structured follow-up.

Neuroleptics — by generic name

All require prescription. Chlorpromazine and haloperidol are widely available generically by virtue of their psychiatric history. Use in pain is almost always hospital-based (emergency or palliative) — chronic outpatient prescription in common pain is marginal in terms of evidence.

Clinical observation: quetiapine for insomnia in chronic pain is a widespread practice but off-label and not recommended by guidelines. For insomnia associated with chronic pain, low-dose amitriptyline, trazodone, or non-pharmacologic interventions (sleep hygiene, CBT-I) have a more favorable risk-benefit profile — lower metabolic, cognitive, and cardiovascular risk in the long term.

Dosing, interactions, and special populations

Older adults. INCREASED RISK of CV mortality in dementia — FDA black box for the entire class. Avoid as routine; in palliative care, minimum dose + short duration. Risk of falls, confusion, and extrapyramidal symptoms is additive. Cardiac patients. Baseline ECG mandatory — haloperidol IV, ziprasidone, and chlorpromazine prolong QT; in QTc > 450 ms (men) or > 470 ms (women), prudent cardiologic evaluation. Parkinson disease and dementia with Lewy bodies. Relative contraindication to typical agents (worsen rigidity, precipitate falls); in Lewy body disease, severe hypersensitivity is a hallmark of the disease — low-dose quetiapine is "less bad," clozapine is a specialized alternative. Closed-angle glaucoma. Contraindicated (anticholinergics). Pregnant and lactating women. Use in pain is exceptional; when indispensable, shared decision with obstetrician and psychiatrist.

Adverse effects, risks, and contraindications

The risk profile is the main reason use in pain is limited — adverse effects substantial and recurrent, with severe presentations (neuroleptic malignant syndrome, torsades, irreversible tardive dyskinesia). In common chronic pain, where there are alternatives, the risks do not pay off.

Absolute contraindications: hypersensitivity; coma or severe CNS depression; severe blood dyscrasia; prior neuroleptic malignant syndrome; significantly prolonged QT without correction. Relative: Parkinson or Lewy body disease (typicals), closed-angle glaucoma, symptomatic prostatic hypertrophy, severe hepatic/renal failure, pheochromocytoma.

Limitations and what is still not known

The gap is not "perhaps they work in pain and we still don't know" — it is that the evidence consistently does not support use in common chronic pain, while the risks are consistently documented. Part of current use derives from historical practice, not robust data.

Central Gaps

Evidence in chronic pain is scarce and heterogeneous. Trials in non-oncologic chronic pain are small, methodologically limited, and frequently negative. No meta-analysis justifies routine use in low back pain, fibromyalgia, peripheral neuropathy, or migraine prophylaxis. Individual predictors of response are not established — unlike other classes (carbamazepine in trigeminal neuralgia, NNT ~2-3), there is no biomarker or subgroup in common chronic pain that allows confidently predicting benefit.

Long-term data on analgesic use are absent — what is known comes from psychiatry, where the decision context is distinct. Off-label prescription of quetiapine/olanzapine for "insomnia in chronic pain" is a practice with significant risk and doubtful benefit: the hypnotic literature does not support low-dose neuroleptics outside of specific contexts.

Relationship with medical acupuncture

The practical interaction between medical acupuncture and neuroleptics is low — the use scenarios diverge (neuroleptics in hospital emergencies or palliative care; acupuncture predominantly outpatient). There is no pharmacologic combinatorial restriction. In palliative care, acupuncture may offer relief of nausea and anxiety without the adverse effects of antipsychotics — the classic point PC-6 (Neiguan) has consistent literature in postoperative and chemotherapy-induced nausea and vomiting.

When to seek medical help

Acute use in emergency settings (migraine) occurs in the hospital environment without prior decision by the patient. In outpatient use (palliative or off-label), some signs warrant early contact with the attending physician, others characterize a clinical emergency.